On November 20, 2023, Wedbush analyst David Nierengarten made a significant decision regarding 2Seventy Bio Inc. (NASDAQ: TSVT). He downgraded the company’s rating from Outperform to Neutral and set a new price target of $2. This change in stance was influenced by the recent announcement from an FDA panel. Nierengarten believes that there is currently no clear catalyst that could drive the company’s shares in the near future. It is worth noting that the previous price target was $4, indicating a substantial decrease. The current average target price stands at $9.333.
2seventy bio, Inc.
TSVT
Buy
Updated on: 02/12/2023
Financial Health
Healthy
Debt to equity ratio: Buy
Price to earnings ratio: Neutral
Price to book ratio: Neutral
DCF: Strong Buy
ROE: Buy
TSVT Stock Performance Declines on November 20, 2023: Financial Analysis and Future Outlook
On November 20, 2023, TSVT (ticker symbol) experienced a decline in its stock performance. The previous day’s closing price was $2.12, while the stock opened at $1.88 on November 20th. Throughout the day, the stock traded within a range of $1.68 to $1.88. The trading volume for the day was 128,872 shares, significantly lower than the average volume of 1,588,577 shares over the past three months.
TSVT, with a market capitalization of $107.0M, operates in the Health Technology sector and falls under the Pharmaceuticals: Major industry. The company’s earnings growth has been impressive, with a growth rate of 42.44% last year and a projected growth rate of 36.75% this year.
In terms of revenue growth, TSVT has shown a substantial increase of 67.81% in the past year. However, the company’s financials reveal a negative net profit margin of -277.77%.
The stock’s price-to-sales ratio stands at 3.65, indicating that investors are willing to pay $3.65 for every dollar of sales generated by the company. On the other hand, the price-to-book ratio is 0.26, which implies that the stock is currently undervalued based on its book value.
Looking ahead, TSVT’s next reporting date is scheduled for March 19, 2024. Analysts forecast an earnings per share (EPS) of -$1.06 for the current quarter, indicating a potential loss.
Despite the negative financials, TSVT operates in the promising Health Technology sector. However, investors should carefully evaluate the company’s financial performance and keep an eye on its ability to turn a profit in the future.
Please note that the information provided is based on data sourced from CNN Money and represents the stock performances of TSVT on November 20, 2023. Investors should conduct thorough research and consult with financial professionals before making any investment decisions.
Promising Stock Performance of 2Seventy Bio Inc (TSVT) with Positive Analyst Forecasts and Consensus Buy Rating
On November 20, 2023, the stock performance of 2Seventy Bio Inc (TSVT) showed promising signs based on the information provided. According to data from CNN Money, six analysts have offered 12-month price forecasts for TSVT, with a median target of $7.00. The high estimate stands at $20.00, while the low estimate is $4.00. This median estimate represents a significant increase of 312.98% from the last price of $1.70.
Furthermore, the current consensus among eight polled investment analysts is to buy stock in 2Seventy Bio Inc. This rating has remained steady since October, indicating a consistent positive sentiment towards the company’s stock.
In terms of financial performance, the current quarter’s earnings per share for 2Seventy Bio Inc stood at -$1.06. While this figure represents a loss, it is important to consider the context and potential future growth opportunities. Additionally, the company reported sales of $42.6 million for the same period, indicating a significant revenue stream.
Investors should take note of the reporting date for this financial information, which is March 19. This means that the data provided is not the most up-to-date, and it is crucial to stay informed about any recent developments or announcements from 2Seventy Bio Inc that may impact its stock performance.
Overall, based on the information provided, 2Seventy Bio Inc’s stock performance on November 20, 2023, appears positive and promising. The median target price forecast by analysts suggests a substantial increase in value, and the consensus among investment analysts is to buy the stock. However, investors should conduct further research and stay updated on the company’s financial performance and any relevant news or events that may impact its stock performance.
Discussion about this post